ArrayExpress Uploader03775free of disease after initial treatmentlymph nodealive55MaliveCHOP6-RITU5.13DLBCGCB2Afree of disease after initial treatmentlymph nodealive54FaliveCHOP6-RITU5.62DLBCABC3Afree of disease after initial treatmentlymph nodealive77MaliveCVPP1-DOXO-CYCL5-RITU5.96DLBCABC3BElymphoma deathlymph nodedead62MdeadCHOP2-RITU0.73DLBCGCB1Afree of disease after initial treatmentlymph nodealive73FaliveCHOP6-RITU5.48DLBCGCBnot specifiedfree of disease after treatment for first relapselymph nodealive72MdeadCHOP6-RITU-RAD7.32DLBCABC4Blymphoma deathlymph nodedead57MdeadCHOP8-RITU0.63DLBCGCB3AEfree of disease after initial treatmentlymph nodealive66MaliveCHOP4-RITU2.48DLBCABC1Alymphoma deathlymph nodedead73MdeadCHOP3-RITU-RAD1.29COMPOSITE (>50% DLBCL, remaining FL)NC2Afree of disease after initial treatmentlymph nodealive56MaliveCHOP6-RITU5.08DLBCGCB4Afree of disease after initial treatmentGIalive53MaliveCHOP6-RITU2.87DLBCGCBnot specifiedfree of disease after initial treatmentlymph nodealive77MaliveCHOP6-RITU5.37DLBCGCB4Bfree of disease after initial treatmenttonsilalive23MaliveCHOP3-RITU-RAD5.07DLBCNC2AElymphoma deathlymph nodedead67MdeadCHOP-RITU0.94DLBCABC4Alymphoma deathspleendead21MdeadCHOP2-RITU-SPLE0.4DLBCNC4Bdeath unrelatedlymph nodedead80FaliveCHOP(CEOP)1-RITU3.2DLBCGCB1Alymphoma deathlymph nodedead71FdeadCHOP-RITU0.03DLBCABC2AEfree of disease after initial treatmentspleenalive73MaliveSPLE-CHOP-RITU-RAD3.76DLBCNC2BEfree of disease after initial treatmentlymph nodealive59MaliveCHOP3-RITU-RAD3.27DLBCGCB2Afree of disease after initial treatmentlymph nodealive73MaliveCHOP8-RITU-G31392.69DLBCNC3Alymphoma deathlymph nodedead49MdeadCHOP1-RITU0.16DLBCABC3AEfree of disease after initial treatmentspleenalive56MaliveCHOP6-RITU2.86DLBCGCB4Bfree of disease after initial treatmentthyroidalive57FaliveCHOP3-RITU-RAD2.66DLBCGCB1AEfree of disease after initial treatmentGIalive92FaliveCHOP5-RITU2.19DLBCGCB2BEfree of disease after treatment for first relapseENTalive51MdeadCHOP6-RITU2.47DLBCABC2AEfree of disease after initial treatmentlymph nodealive16FaliveCHOP4-RITU2.5DLBCNC1Afree of disease after initial treatmentlymph nodealive52FaliveCHOP6-RITU-RITUMAIN1.84DLBCGCB4Afree of disease after initial treatmentlymph nodealive22MaliveCHOP4-RITU1.82DLBCGCB2Alymphoma deathlymph nodedead82FdeadFLUD10.28DLBCGCB3AReceiving treatment for first relapselymph nodealive47MdeadCHOP6-RITU2.37DLBCGCB4Bfree of disease after initial treatmentlymph nodealive80FaliveCHOP3-RITU-RAD5.82DLBCGCB3Afree of disease after initial treatmentlymph nodealive79MaliveCHOP6-RITU2.67DLBCGCB2Alymphoma deathlymph nodedead57MdeadCHOP6-RITU0.9DLBCABC4Bfree of disease after initial treatmentlymph nodealive60MaliveCHOP8-RITU-RAD5.11DLBCGCB2Bfree of disease after initial treatmentlymph nodealive68FaliveCHOP7-RITU4.49DLBCGCB3Bfree of disease after initial treatmentlymph nodealive66MaliveCHOP6-RITU2.81DLBCGCB3Afree of disease after initial treatmentlymph nodealive69MaliveCHOP-RITU-ABVD4.12DLBCGCB4Bfree of disease after initial treatmentlymph nodealive84MaliveCHOP6-RITU2.74DLBCABC3Atoxic deathlymph nodedead73FdeadCHOP4-RITU0.52DLBCABC2Afree of disease after initial treatmentlymph nodealive19MaliveCHOP6-RITU2.61DLBCGCB1AElymphoma deathlymph nodedead81MdeadCHOP6-RITU-RAD1.41DLBCABC3Bfree of disease after treatment for first relapsespleenalive65MdeadCHOP6-RITU4.29DLBCGCB4Bfree of disease after initial treatmentlymph nodealive62MaliveCHOP3-RITU-RAD4.49DLBCGCB2Afree of disease after initial treatmentlymph nodealive50MaliveCHOP3-RITU-RAD3.67DLBCGCB1Alymphoma deathgastricdead78MdeadDOXO-CYCL2-RITU0.62DLBCNC4Bfree of disease after initial treatmentGIalive68MaliveCHOP6-RITU1.55DLBCGCBnot specifiedfree of disease after initial treatmentlymph nodealive61MaliveCHOP6-RITU2.3DLBCGCB4Bfree of disease after initial treatmentlymph nodealive65MaliveCHOP7-RITU1.88DLBCNC2AWith disease, after initial treatmentlymph nodealive54MaliveCYCL1-CHOP6-RITU1.65DLBCABC3Afree of disease after initial treatmentbreastalive62FaliveCHOP3-RITU-RAD1.97DLBCNC1AEfree of disease after initial treatmentlymph nodealive50MaliveCHOP6-RITU1.78DLBCABCnot specifiedfree of disease after initial treatmentlymph nodealive60MaliveCHOP6-RITU1.63DLBCABC3AWith disease, after initial treatmentENTalive80FaliveCVP1-RITU,CHOP5-RITU1.74DLBCGCB3AEfree of disease after initial treatmentlymph nodealive68FaliveCHOP4-RITU0.93DLBCGCB1Afree of disease after initial treatmentlymph nodealive76MaliveCHOP5-RITU1.25DLBCGCB3Afree of disease after initial treatmentlymph nodealive45MaliveCHOP-RITU0.68DLBCABC2Bfree of disease after initial treatmentlymph nodealive69FaliveCHOP4-RITU0.99DLBCABC2AEfree of disease after initial treatmentlymph nodealive68FaliveCHOP6-RITU0.43DLBCGCB3BWith disease, after initial treatmentlymph nodealive49FaliveCHOP4-RITU1.54DLBCGCB3Afree of disease after initial treatmentlymph nodealive76MaliveCHOP4-RITU0.99DLBCGCB1Afree of disease after initial treatmentlymph nodealive78MaliveCHOP8-RITU1.02COMPOSITE (>50% DLBCL, remaining FL)GCB2Afree of disease after initial treatmenttestisalive67MaliveCHOP6-RITU-RAD1.14DLBCABC2AEfree of disease after initial treatmentlymph nodealive77MaliveCHOP6-RITU0.99DLBCGCB2Bfree of disease after initial treatmentlymph nodealive68MaliveCHOP4-RITU0.74DLBCGCB1Afree of disease after initial treatmentlymph nodealive67MaliveCHOP6-RITU-RAD0.56COMPOSITE (>50% DLBCL, remaining FL)GCB2Afree of disease after initial treatmentlymph nodealive58MaliveCHOP6-RITU0.73DLBCGCB2Afree of disease after initial treatmentlymph nodealive58MaliveCHOP6-RITU-RITUMAIN0.79COMPOSITE (>50% DLBCL, remaining FL)GCB3Bfree of disease after initial treatmentlymph nodealive73MaliveCHOP4-RITU0.64DLBCABC1Anot specifiedlymph nodealive57FdeadCHOP610.29DLBCABC3Aarrayexpress_sid4We performed DNA methylation (HELP array) and gene expression profiling in 69 samples of diffuse large B cell lymphoma (DLBCL). First, by...20610814E-GEOD-23501/profile/8773/arrayexpressuploader1169celllymphomaDec.12, 2014Falsedna-methylation-signatures-define-molecular-subtypE-GEOD-23501_A-AFFY-44DNA methylation signatures define molecular subtypes of Diffuse Large B Cell LymphomaSep.15, 2014We performed DNA methylation (HELP array) and gene expression profiling in 69 samples of diffuse large B cell lymphoma (DLBCL). First, by gene expression, two molecular subtypes of DLBCL termed as "germinal center B cell-like" (GCB) and "activated B cell-like" (ABC) DLBCL were assigned to the 69 DLBCL cases. Then, the supervised analysis using HELP data revealed strikingly different DNA promoter methylation patterns in the two molecular DLBCL subtypes. These data provide epigenetic evidence that the DLBCL subtypes are distinct diseases that utilize different oncogenic pathways. The retrospective study included RNA and DNA extracted from 69 clinical samples. This submission represents the gene expression component of the study.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23501humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-23501/samples/